Gene Therapy Market by Vectors (Non-viral(Oligonucleotides), Viral(Retroviral, Adeno-associated)), Indication (Cancer, Neurological, Hepatological Diseases, Duchenne Muscular Dystrophy), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2027
[159 Pages Report] The global gene therapy market is projected to reach USD 17.2 billion by 2027 from USD 7.3 billion in 2022, at a CAGR of 18.6% during the forecast period. Factors such as growing approvals of gene therapy products, rising investment in research and development of gene therapies, and are driving the market growth. However, high cost of gene therapy is restraining the growth of this market.
Attractive Opportunities in the Gene Therapy Market
To know about the assumptions considered for the study, Request for Free Sample Report
Global gene therapy Market Dynamics
DRIVER: Funding for gene therapy research
Gene therapy is one of the latest treatment methods in the healthcare industry. It has shown promising results in treating cancer and other genetic diseases. As a result, the focus on gene therapy research has increased over the last few years. In addition, many companies focus on growth opportunities in this market by launching new and advanced products. For example:
- In March 2022, the National Heart Lung and Blood Institute granted USD 12 million to an Indiana University School of Medicine researcher. The grant is for exploring major themes in a gene therapy approach to safer and potentially curative treatments for hemophilia.
- In May 2019, Locana, Inc., a leading RNA-targeting gene therapy company, received USD 55 million in Series A financing led by ARCH Venture Partners, with participation from Temasek and Lightstone Ventures (all existing investors). The company will utilize this fund for its RNA-targeting gene therapy pipeline programs.
OPPORTUNITY: Strong product pipeline
Gene therapy is a promising revenue-generation area for pharmaceutical & biotechnology companies. Currently, most key players are focusing on new gene therapy products to capitalize on the growth opportunities in this market. Some of these products are in the pre-clinical stage, while others are in the clinical phase and expected to secure approval in the coming years. In addition, companies operating in the gene therapy market are focusing on various disease areas, including hemophilia A & B, Fabry disease, wet age-related macular degeneration, mucopolysaccharidosis Type II, ornithine transcarbamylase (OTC) deficiency, achromatopsia, and multiple myeloma. As a result, the patient pool for gene therapies is expected to increase in the coming years.
CHALLENGE: High treatment cost
Currently, the cost of gene therapies is very high, and it can reach up to USD 1 million for one patient depending on the disease condition. Most gene therapy products in the US and EU are covered under reimbursement programs. However, it is difficult for people not covered under insurance to afford such high-cost treatments.
The non-viral vectors segment dominated the gene therapy market in 2021:
On the basis of vectors, the gene therapy market is segmented into non-viral vectors and viral vectors. Non-viral vectors accounted for the larger market share in 2021. Factors such as less immunogenicity of non-viral vectors in comparison to viral vectors coupled with easier mass production of non-viral vectors are driving the growth of this segment.
To know about the assumptions considered for the study, download the pdf brochure
North America was the largest regional market for gene therapy market in 2021.
North America accounted for the largest share of the global gene therapy market in 2021. The significant government and private investments to develop advanced gene therapy products, the high growing adoption rate of these products, and the presence of key market players in the region attribute to a large share of North America in the gene therapy market.
Key Market Players
Key players in the global gene therapy market include Biogen (US), Sarepta Therapeutics (US), Gilead Sciences, Inc. (US), Amgen, Inc. (US), Novartis AG (Switzerland), Orchard Therapeutics Plc (UK), Spark Therapeutics, Inc. (A Part Of ύF. Hoffmann-La Roche) (US), AGC Biologics (US), Anges, Inc. (Japan), Bluebird Bio, Inc. (US), Jazz Pharmaceuticals Plc (Ireland), Dynavax Technologies (US), Human Stem Cells Institute (Russia), Sibiono Genetech Co., Ltd. (China), Shanghai Sunway Biotech Co., Ltd. (China), Uniqure N.V. (Netherland), Gensight Biologics S.A. (France), Celgene Corporation (A Bristol-Myers Squibb Company) (US), Cellectis (France), Sangamo Therapeutics (US), Mustang Bio (US), AGTC (Applied Genetic Technologies Corporation) (US), and Poseida Therapeutics, Inc. (US).
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market size available for years |
20212027 |
|
Base year considered |
2021 |
|
Forecast period |
20222027 |
|
Forecast units |
Value (USD) |
|
Segments covered |
Vectors, Indication, Delivery Method, and Region |
|
Geographies covered |
North America, Europe, Asia Pacific, and Rest of the World |
|
Companies covered |
Biogen (US), Sarepta Therapeutics (US), Gilead Sciences, Inc. (US), Amgen, Inc. (US), Novartis Ag (Switzerland), Orchard Therapeutics Plc (UK), Spark Therapeutics, Inc. (A Part Of ύF. Hoffmann-La Roche) (US), Agc Biologics (US), Anges, Inc. (Japan), Bluebird Bio, Inc. (US), Jazz Pharmaceuticals Plc (Ireland), Dynavax Technologies (US), Human Stem Cells Institute (Russia), Sibiono Genetech Co., Ltd. (China), Shanghai Sunway Biotech Co., Ltd. (China), Uniqure N.V. (Netherland), Gensight Biologics S.A. (France), Celgene Corporation (A Bristol-Myers Squibb Company) (US), Cellectis (France), Sangamo Therapeutics (US), Mustang Bio (US), AGTC (Applied Genetic Technologies Corporation) (US), Poseida Therapeutics, Inc. (US) |
This report categorizes the gene therapy market into the following segments and subsegments:
Gene Therapy Market, by Vectors
- Non-viral Vectors
- Oligonucleotides
- Other Non-viral Vectors
- Viral Vectors
- Retro Viral Vectors
- Adeno-associated Virus Vectors
- Other Viral Vectors
Gene Therapy Market, by Indication
- Neurological Diseases
- Cancer
- DMD (Duchenne Muscular Dystrophy)
- Hepatological Diseases
- Other Indications
Gene Therapy Market, by Delivery Method
- In Vivo
- Ex Vivo
gene therapy Market, by Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- China
- Japan
- Rest of Asia Pacific (RoAPAC)
- Rest of the World (RoW)
Recent Developments
- In February 2022, Sarepta Therpeutics (US) announced a collaboration to use GenEdits NanoGalaxy platform and Sareptas gene editing technology to develop gene editing therapeutics to treat neuromuscular diseases.
- In May 2022, Novartis AG (Switzerland) received FDA approval for KYMRIAH for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Frequently Asked Questions (FAQ):
How big is the Gene Therapy Market ?
Gene Therapy Market worth $17.2 billion by 2027.
What is the growth rate of Gene Therapy Market ?
Gene Therapy Market grows at a CAGR of 18.6% during the forecast period.
Who are the key players in the gene therapy market?
Key players in the global gene therapy Market include Biogen (US), Sarepta Therapeutics (US), Gilead Sciences, Inc. (US), Amgen, Inc. (US), Novartis AG (Switzerland), Orchard Therapeutics Plc (UK), Spark Therapeutics, Inc. (A Part Of ύF. Hoffmann-La Roche) (US), AGC Biologics (US), Anges, Inc. (Japan), Bluebird Bio, Inc. (US), Jazz Pharmaceuticals Plc (Ireland), Dynavax Technologies (US), Human Stem Cells Institute (Russia), Sibiono Genetech Co., Ltd. (China), Shanghai Sunway Biotech Co., Ltd. (China), Uniqure N.V. (Netherland), Gensight Biologics S.A. (France), Celgene Corporation (A Bristol-Myers Squibb Company) (US), Cellectis (France), Sangamo Therapeutics (US), Mustang Bio (US), AGTC (Applied Genetic Technologies Corporation) (US), and Poseida Therapeutics, Inc. (US).
Which vectors segment dominates the gene therapy market?
In 2021, non-viral vectors accounted for the larger market share. Factors such as less immunogenicity of non-viral vectors in comparison to viral vectors coupled with easier mass production of non-viral vectors are driving the growth of this segment.
Which indication segment of the gene therapy market is expected to witness the highest growth?
Cancer segment is expected to witness the highest growth during the forecast period. Increasing investment in research and development of gene therapies to treat cancer coupled with rising cases of cancer are the major factors driving the segmental growth.
What is the size for the gene therapy market?
The global gene therapy market is estimated to grow from USD 7.3 billion in 2022 to reach USD 17.2 billion by 2027, at a CAGR of 18.6% during the forecast period.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 23)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 26)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
FIGURE 2 KEY DATA FROM SECONDARY SOURCES
2.1.2 PRIMARY DATA
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.2 COMPANY REVENUE ANALYSIS
FIGURE 4 COMPANY REVENUE ANALYSIS
2.2.3 GROWTH FORECAST
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 5 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RISK ASSESSMENT
3 EXECUTIVE SUMMARY (Page No. - 32)
FIGURE 6 GENE THERAPY MARKET, BY VECTOR, 2022 VS. 2027 (USD MILLION)
FIGURE 7 GENE THERAPY MARKET, BY DELIVERY METHOD, 2022 VS. 2027 (USD MILLION)
FIGURE 8 GENE THERAPY MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 9 GENE THERAPY MARKET: REGIONAL SNAPSHOT
4 PREMIUM INSIGHTS (Page No. - 35)
4.1 GENE THERAPY MARKET OVERVIEW
FIGURE 10 HIGH INCIDENCE OF CANCER & OTHER TARGETED DISEASES TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR (2021)
FIGURE 11 NON-VIRAL VECTORS DOMINATE NORTH AMERICAN GENE THERAPY MARKET
4.3 GEOGRAPHICAL SNAPSHOT OF THE GENE THERAPY MARKET
FIGURE 12 APAC COUNTRIES TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 37)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 13 GENE THERAPY MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 High incidence of cancer and other target diseases
TABLE 1 NUMBER OF NEW CANCER CASES, 2020 VS. 2025
5.2.1.2 Product approvals
TABLE 2 PRODUCT APPROVALS, 20152021
5.2.1.3 Funding for gene therapy research
5.2.2 OPPORTUNITIES
5.2.2.1 Strong product pipeline
TABLE 3 GENE THERAPY MARKET: INDICATIVE LIST OF PIPELINE DRUGS
5.2.3 CHALLENGES
5.2.3.1 High treatment costs
TABLE 4 PRICE OF GENE THERAPY PRODUCTS, 2021
5.3 PRICING ANALYSIS
5.4 TECHNOLOGY ANALYSIS
FIGURE 14 KEY STEPS IN GENE THERAPY
5.5 SUPPLY CHAIN ANALYSIS
5.5.1 PROMINENT COMPANIES
5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES (SMES)
5.5.3 END USERS
FIGURE 15 GENE THERAPY MARKET: SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS OF GENE THERAPY MARKET
TABLE 5 STAKEHOLDERS IN THE GENE THERAPY ECOSYSTEM AND THEIR ROLES
5.7 KEY CONFERENCES AND EVENTS IN 20222023
TABLE 6 GENE THERAPY MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.8 REGULATORY ANALYSIS
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 PORTERS FIVE FORCES ANALYSIS
TABLE 11 GENE THERAPY MARKET: PORTERS FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF SUPPLIERS
5.9.4 BARGAINING POWER OF BUYERS
5.9.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 16 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GENE THERAPY PRODUCTS
5.10.2 BUYING CRITERIA FOR GENE THERAPY PRODUCTS
FIGURE 17 KEY BUYING CRITERIA FOR END USERS
6 GENE THERAPY MARKET, BY VECTOR (Page No. - 49)
6.1 INTRODUCTION
TABLE 12 GENE THERAPY MARKET, BY VECTOR, 20202027 (USD MILLION)
6.2 NON-VIRAL VECTORS
TABLE 13 GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY REGION, 20202027 (USD MILLION)
TABLE 14 GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
6.2.1 OLIGONUCLEOTIDES
6.2.1.1 Oligonucleotides account for the largest share of the non-viral vectors market
TABLE 15 GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY REGION, 20202027 (USD MILLION)
6.2.2 OTHER NON-VIRAL VECTORS
TABLE 16 GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY REGION, 20202027 (USD MILLION)
6.3 VIRAL VECTORS
TABLE 17 GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION, 20202027 (USD MILLION)
TABLE 18 GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
6.3.1 RETROVIRAL VECTORS
TABLE 19 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY REGION, 20202027 (USD MILLION)
TABLE 20 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
6.3.1.1 Gamma-retroviral vectors
6.3.1.1.1 Availability of wide range of gamma-retroviral vectors supports market growth
TABLE 21 GENE THERAPY MARKET FOR GAMMA-RETROVIRAL VECTORS, BY REGION, 20202027 (USD MILLION)
6.3.1.2 Lentiviral vectors
6.3.1.2.1 North America to dominate lentiviral vectors market
TABLE 22 GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY REGION, 20202027 (USD MILLION)
6.3.2 ADENO-ASSOCIATED VIRUS VECTORS
6.3.2.1 Potential applications in in vivo applications to drive interest in AAV vectors
TABLE 23 GENE THERAPY MARKET FOR AAV VECTORS, BY REGION, 20202027 (USD MILLION)
6.3.3 OTHER VIRAL VECTORS
TABLE 24 GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY REGION, 20202027 (USD MILLION)
7 GENE THERAPY MARKET, BY INDICATION (Page No. - 56)
7.1 INTRODUCTION
TABLE 25 GENE THERAPY MARKET, BY INDICATION, 20202027 (USD MILLION)
7.2 NEUROLOGICAL DISEASES
7.2.1 NEUROLOGICAL DISEASES TO FORM THE LARGEST INDICATION SEGMENT IN THIS MARKET
TABLE 26 GENE THERAPY MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 20202027 (USD MILLION)
7.3 CANCER
7.3.1 GROWING DEMAND FOR CANCER THERAPIES TO DRIVE MARKET GROWTH
TABLE 27 NUMBER OF NEW CANCER CASES, BY TYPE, 20202040
TABLE 28 GENE THERAPY MARKET FOR CANCER, BY REGION, 20202027 (USD MILLION)
7.4 DUCHENNE MUSCULAR DYSTROPHY
7.4.1 RISING PREVALENCE OF DMD TO SUPPORT MARKET GROWTH
TABLE 29 GENE THERAPY MARKET FOR DMD, BY REGION, 20202027 (USD MILLION)
7.5 HEPATOLOGICAL DISEASES
7.5.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS TO SUPPORT MARKET GROWTH
TABLE 30 GENE THERAPY MARKET FOR HEPATOLOGICAL DISEASES, BY REGION, 20202027 (USD MILLION)
7.6 OTHER INDICATIONS
TABLE 31 GENE THERAPY MARKET FOR OTHER INDICATIONS, BY REGION, 20202027 (USD MILLION)
8 GENE THERAPY MARKET, BY DELIVERY METHOD (Page No. - 62)
8.1 INTRODUCTION
TABLE 32 GENE THERAPY MARKET, BY DELIVERY METHOD, 20202027 (USD MILLION)
8.2 IN VIVO GENE THERAPY
8.2.1 IN VIVO GENE THERAPY TO DOMINATE MARKET
TABLE 33 IN VIVO GENE THERAPY MARKET, BY REGION, 20202027 (USD MILLION)
8.3 EX VIVO GENE THERAPY
8.3.1 EX VIVO GENE THERAPY SEGMENT TO WITNESS HIGH GROWTH
TABLE 34 EX VIVO GENE THERAPY MARKET, BY REGION, 20202027 (USD MILLION)
9 GENE THERAPY MARKET, BY REGION (Page No. - 65)
9.1 INTRODUCTION
TABLE 35 GENE THERAPY MARKET, BY REGION, 20202027 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 18 NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT
TABLE 36 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 37 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR, 20202027 (USD MILLION)
TABLE 38 NORTH AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 39 NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 40 NORTH AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 41 NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 20202027 (USD MILLION)
TABLE 42 NORTH AMERICA: GENE THERAPY MARKET, BY INDICATION, 20202027 (USD MILLION)
9.2.1 US
9.2.1.1 US dominates the global gene therapy market
TABLE 43 LIST OF GENE THERAPY PIPELINE CANDIDATES OF US-BASED COMPANIES
TABLE 44 US FDA GENE THERAPY PRODUCT APPROVALS
TABLE 45 US: GENE THERAPY MARKET, BY VECTOR, 20202027 (USD MILLION)
TABLE 46 US: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 47 US: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 48 US: RETROVIRAL VECTORS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 49 US: GENE THERAPY MARKET, BY DELIVERY METHOD, 20202027 (USD MILLION)
TABLE 50 US: GENE THERAPY MARKET, BY INDICATION, 20202027 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Growing burden of cancer supports market growth in Canada
TABLE 51 CANADA: GENE THERAPY MARKET, BY VECTOR, 20202027 (USD MILLION)
TABLE 52 CANADA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 53 CANADA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 54 CANADA: RETROVIRAL VECTORS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 55 CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD, 20202027 (USD MILLION)
TABLE 56 CANADA: GENE THERAPY MARKET, BY INDICATION, 20202027 (USD MILLION)
9.3 EUROPE
TABLE 57 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 58 EUROPE: GENE THERAPY MARKET, BY VECTOR, 20202027 (USD MILLION)
TABLE 59 EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 60 EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 61 EUROPE: RETROVIRAL VECTORS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 62 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 20202027 (USD MILLION)
TABLE 63 EUROPE: GENE THERAPY MARKET, BY INDICATION, 20202027 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Germany dominates European gene therapy market
TABLE 64 GERMANY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 65 GERMANY: GENE THERAPY MARKET, BY VECTOR, 20202027 (USD MILLION)
TABLE 66 GERMANY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 67 GERMANY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 68 GERMANY: RETROVIRAL VECTORS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 69 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD, 20202027 (USD MILLION)
TABLE 70 GERMANY: GENE THERAPY MARKET, BY INDICATION, 20202027 (USD MILLION)
9.3.2 FRANCE
9.3.2.1 Increasing cancer incidence to support market growth
TABLE 71 FRANCE: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 72 FRANCE: GENE THERAPY MARKET, BY VECTOR, 20202027 (USD MILLION)
TABLE 73 FRANCE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 74 FRANCE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 75 FRANCE: RETROVIRAL VECTORS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 76 FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD, 20202027 (USD MILLION)
TABLE 77 FRANCE: GENE THERAPY MARKET, BY INDICATION, 20202027 (USD MILLION)
9.3.3 UK
9.3.3.1 Rising incidence of melanoma to support market growth in UK
TABLE 78 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 79 UK: GENE THERAPY MARKET, BY VECTOR, 20202027 (USD MILLION)
TABLE 80 UK: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 81 UK: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 82 UK: RETROVIRAL VECTORS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 83 UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 20202027 (USD MILLION)
TABLE 84 UK: GENE THERAPY MARKET, BY INDICATION, 20202027 (USD MILLION)
9.3.4 ITALY
9.3.4.1 High incidence of targeted diseases and increasing healthcare spending to drive Italian market growth
TABLE 85 ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 86 ITALY: GENE THERAPY MARKET, BY VECTOR, 20202027 (USD MILLION)
TABLE 87 ITALY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 88 ITALY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 89 ITALY: RETROVIRAL VECTORS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 90 ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD, 20202027 (USD MILLION)
TABLE 91 ITALY: GENE THERAPY MARKET, BY INDICATION, 20202027 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Rising cancer incidence and increasing healthcare expenditure to support market growth in Spain
TABLE 92 SPAIN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 93 SPAIN: GENE THERAPY MARKET, BY VECTOR, 20202027 (USD MILLION)
TABLE 94 SPAIN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 95 SPAIN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 96 SPAIN: RETROVIRAL VECTORS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 97 SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD, 20202027 (USD MILLION)
TABLE 98 SPAIN: GENE THERAPY MARKET, BY INDICATION, 20202027 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 99 ROE: GENE THERAPY MARKET, BY VECTOR, 20202027 (USD MILLION)
TABLE 100 ROE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 101 ROE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 102 ROE: RETROVIRAL VECTORS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 103 ROE: GENE THERAPY MARKET, BY DELIVERY METHOD, 20202027 (USD MILLION)
TABLE 104 ROE: GENE THERAPY MARKET, BY INDICATION, 20202027 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 19 ASIA PACIFIC: GENE THERAPY MARKET SNAPSHOT
TABLE 105 ASIA PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 106 ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 20202027 (USD MILLION)
TABLE 107 ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 108 ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 109 ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 110 ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 20202027 (USD MILLION)
TABLE 111 ASIA PACIFIC: GENE THERAPY MARKET, BY INDICATION, 20202027 (USD MILLION)
9.4.1 JAPAN
9.4.1.1 Japan dominates the APAC gene therapy market
TABLE 112 JAPAN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 113 JAPAN: GENE THERAPY MARKET, BY VECTOR, 20202027 (USD MILLION)
TABLE 114 JAPAN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 115 JAPAN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 116 JAPAN: RETROVIRAL VECTORS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 117 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD, 20202027 (USD MILLION)
TABLE 118 JAPAN: GENE THERAPY MARKET, BY INDICATION, 20202027 (USD MILLION)
9.4.2 CHINA
9.4.2.1 Rising prevalence of cancer and established base for gene therapy to support market growth in China
TABLE 119 CHINA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 120 CHINA: GENE THERAPY MARKET, BY VECTOR, 20202027 (USD MILLION)
TABLE 121 CHINA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 122 CHINA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 123 CHINA: RETROVIRAL VECTORS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 124 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD, 20202027 (USD MILLION)
TABLE 125 CHINA: GENE THERAPY MARKET, BY INDICATION, 20202027 (USD MILLION)
9.4.3 REST OF ASIA PACIFIC
TABLE 126 ROAPAC: GENE THERAPY MARKET, BY VECTOR, 20202027 (USD MILLION)
TABLE 127 ROAPAC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 128 ROAPAC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 129 ROAPAC: RETROVIRAL VECTORS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 130 ROAPAC: GENE THERAPY MARKET, BY DELIVERY METHOD, 20202027 (USD MILLION)
TABLE 131 ROAPAC: GENE THERAPY MARKET, BY INDICATION, 20202027 (USD MILLION)
9.5 REST OF THE WORLD
TABLE 132 ROW: GENE THERAPY MARKET, BY VECTOR, 20202027 (USD MILLION)
TABLE 133 ROW: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 134 ROW: GENE THERAPY MARKET, BY DELIVERY METHOD, 20202027 (USD MILLION)
TABLE 135 ROW: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 20202027 (USD MILLION)
TABLE 136 ROW: RETROVIRAL VECTORS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 137 ROW: GENE THERAPY MARKET, BY INDICATION, 20202027 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 102)
10.1 OVERVIEW
FIGURE 20 KEY DEVELOPMENTS IN THE GENE THERAPY MARKET
10.2 MARKET SHARE ANALYSIS, 2021
FIGURE 21 GENE THERAPY MARKET SHARE ANALYSIS, 2021
TABLE 138 GENE THERAPY MARKET: DEGREE OF COMPETITION
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 22 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN GENE THERAPY, 20192021
10.4 COMPANY EVALUATION QUADRANT
10.4.1 STARS
10.4.2 EMERGING LEADERS
10.4.3 PERVASIVE PLAYERS
10.4.4 PARTICIPANTS
FIGURE 23 GENE THERAPY MARKET: COMPANY EVALUATION QUADRANT, 2021
10.5 COMPANY FOOTPRINT ANALYSIS
10.5.1 PRODUCT FOOTPRINT OF COMPANIES
TABLE 139 GENE THERAPY MARKET: COMPANY PRODUCT FOOTPRINT (2021) ACROSS INDICATIONS
10.6 COMPETITIVE SCENARIO
TABLE 140 PRODUCT APPROVALS, 20182022
TABLE 141 DEALS, 20182022
TABLE 142 OTHER DEVELOPMENTS, 2018-2022
11 COMPANY PROFILES (Page No. - 110)
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
11.1 BIOGEN
TABLE 143 BIOGEN: BUSINESS OVERVIEW
FIGURE 24 BIOGEN: COMPANY SNAPSHOT
11.2 SAREPTA THERAPEUTICS
TABLE 144 SAREPTA THERAPEUTICS: BUSINESS OVERVIEW
FIGURE 25 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT
11.3 GILEAD SCIENCES, INC.
TABLE 145 GILEAD SCIENCES INC: BUSINESS OVERVIEW
FIGURE 26 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
11.4 AMGEN, INC.
TABLE 146 AMGEN INC: BUSINESS OVERVIEW
FIGURE 27 AMGEN, INC.: COMPANY SNAPSHOT
11.5 NOVARTIS AG
TABLE 147 NOVARTIS AG: BUSINESS OVERVIEW
FIGURE 28 NOVARTIS AG: COMPANY SNAPSHOT
11.6 ORCHARD THERAPEUTICS PLC
TABLE 148 ORCHARD THERAPEUTICS PLC: BUSINESS OVERVIEW
FIGURE 29 ORCHARD THERAPEUTICS PLC: COMPANY SNAPSHOT
11.7 SPARK THERAPEUTICS, INC. (AN F. HOFFMANN-LA ROCHE COMPANY)
TABLE 149 SPARK THERAPEUTICS INC: BUSINESS OVERVIEW
11.8 AGC BIOLOGICS
TABLE 150 AGC BIOLOGICS: BUSINESS OVERVIEW
11.9 ANGES, INC.
TABLE 151 ANGES INC: BUSINESS OVERVIEW
FIGURE 30 ANGES, INC.: COMPANY SNAPSHOT
11.1 BLUEBIRD BIO, INC.
TABLE 152 BLUEBIRD BIO: BUSINESS OVERVIEW
FIGURE 31 BLUEBIRD BIO: COMPANY SNAPSHOT
11.11 JAZZ PHARMACEUTICALS PLC
TABLE 153 JAZZ PHARMACEUTICALS: BUSINESS OVERVIEW
FIGURE 32 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT
11.12 DYNAVAX TECHNOLOGIES
TABLE 154 DYNAVAX TECHNOLOGIES: BUSINESS OVERVIEW
FIGURE 33 DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT
11.13 HUMAN STEM CELLS INSTITUTE
TABLE 155 HUMAN STEM CELLS INSTITUTE: BUSINESS OVERVIEW
11.14 SIBIONO GENETECH CO., LTD.
TABLE 156 SIBIONO GENETECH CO LTD: BUSINESS OVERVIEW
11.15 SHANGHAI SUNWAY BIOTECH CO., LTD.
TABLE 157 SHANGHAI SUNWAY BIOTECH CO LTD: BUSINESS OVERVIEW
11.16 UNIQURE N.V.
TABLE 158 UNIQURE NV: BUSINESS OVERVIEW
11.17 GENSIGHT BIOLOGICS S.A.
TABLE 159 GENSIGHT BIOLOGICS SA: BUSINESS OVERVIEW
11.18 CELGENE CORPORATION (A BRISTOL-MYERS SQUIBB COMPANY)
TABLE 160 CELGENE CORPORATION: BUSINESS OVERVIEW
11.19 CELLECTIS
TABLE 161 CELLECTIS: BUSINESS OVERVIEW
11.2 SANGAMO THERAPEUTICS
TABLE 162 SANGAMO THERAPEUTICS: BUSINESS OVERVIEW
11.21 MUSTANG BIO
TABLE 163 MUSTANG BIO: BUSINESS OVERVIEW
11.22 AGTC (APPLIED GENETIC TECHNOLOGIES CORPORATION)
TABLE 164 AGTC: BUSINESS OVERVIEW
11.23 POSEIDA THERAPEUTICS, INC.
TABLE 165 POSEIDA THERAPEUTICS INC: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12 APPENDIX (Page No. - 153)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information to analyze the global gene therapy market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
The secondary sources referred to for this research study included corporate filings (such as annual reports, SEC filings, and financial statements), research journals, press releases, and trade, business, and professional associations. These secondary sources were used to identify and collect useful information for this extensive, technical, and commercial study of the gene therapy market. Secondary research was mainly used to obtain key information about the industrys total pool of key players, market classification and segmentation according to industry trends to the bottom-most level, market trends, and key developments by both public and private organizations in the gene therapy market.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global gene therapy market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across four major regions, namely, North America, Europe, the Asia Pacific, and Rest of the World. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the gene therapy market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive primary and secondary research.
- The revenues generated from the gene therapy business of leading players have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
Report Objectives
- To define, describe, and forecast the gene therapy market on the basis of vectors, indication, delivery method, and region
- To provide detailed information regarding the major factors influencing the market growth, such as drivers, restraints, opportunities, and challenges
- To strategically analyze the micromarkets with respect to individual growth trends, future prospects, and contributions to the overall gene therapy market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the revenue of the market segments with respect to four main regions, namely, North America (US and Canada), Europe (Germany, France, UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, and the Rest of Asia Pacific), and Rest of the World.
- To profile the key market players and comprehensively analyze their market shares and core competencies
- To track and analyze competitive developments such as product launches, agreements, partnerships, acquisitions, business expansions, and research & development activities in the gene therapy market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the companys specific needs. The following customization options are available for this report:
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
Growth opportunities and latent adjacency in Gene Therapy Market